Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications
Frontiers in Pharmacology · 23.12.2024 · 15
DOI: 10.3389/fphar.2024.1501407 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.12.2024. Verfasst von Xinyue Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Chengdu University of TCM, Chengdu, Sichuan, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system. NEP’s involvement in metabolizing natriuretic peptides, insulin, and enkephalins makes it a promising target for treating cardiovascular and Alzheimer’s diseases. Several NEP inhibitors, such as sacubitril and omapatrilat, have been approved for clinical use, which inhibit NEP activity to prolong the bioactivity of beneficial peptides, thereby exerting therapeutic effects. However, despite the broad clinical application prospects of NEP inhibitors, they still have specific adverse reactions and side effects, such as hypotension, renal impairment, and a potentially increased risk of Alzheimer’s disease. This manuscript comprehensively reviews the progress on single-target and dual-target NEP inhibitors. Dual-target inhibitors often combine with other therapeutic targets, such as angiotensin receptors, to enhance therapeutic effects and reduce adverse reactions. The article also emphasizes these inhibitors' design strategies, structure-activity relationships (SAR), safety, and clinical performance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Stomatology, Chengdu Fifth People's Hospital/The Second Clinical Medical College, Chengdu University of TCM, Chengdu, Sichuan, China.
- Department of Orthodontics, State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Zitieren
APA
Zhang, X., Hu, C., Tian, E., Shen, Y., Liu, W., & Li, J. (2024). Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1501407
Vancouver
Zhang X, Hu C, Tian E, Shen Y, Liu W, Li J. Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1501407
BibTeX
@article{Zhang2024,
author = {Zhang, Xinyue and Hu, Chun and Tian, Erkang and Shen, Yanxin and Liu, Wei and Li, Juan},
title = {Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1501407}
}
EUVIMED